Ozette is a life sciences data startup company that develops an artificial intelligence-enabled immune monitoring platform. It empowers scientists to quickly extract reliable insights from single-cell data across instruments, experiments, and disease states, with a focus on cancer patients. The data can be used by doctors to diagnose and prescribe medication with greater accuracy. In 2020, co-founders Raphael Gottardo, Greg Finak, Ali Ansary, and Evan Greene headquartered the life science company in Seattle, Washington.
Ockam Inc. is a company that specializes in providing a serverless platform for secure Internet-of-Things (IoT) development. Founded in 2017 and headquartered in San Francisco, California, Ockam offers open-source tools that enable developers to create trustworthy IoT systems. Its platform facilitates the interconnection of hardware and software services, allowing for the secure exchange of information between connected devices and cloud services. Ockam's solutions include end-to-end encryption, key management, and mutual authentication, ensuring that data remains secure in transit across complex networks. By connecting application developers, system integrators, and hardware engineers, Ockam simplifies the development process and enhances the trustworthiness of data exchanged within IoT ecosystems.
Rad AI empowers radiologists for the future.
ByHeart, Inc. is an infant nutrition company that develops a range of nutritional food products for infants and babies, focusing on immune, microbiome, cognitive, and digestive health. Founded in 2016 and headquartered in New York, the company operates facilities in Pennsylvania. ByHeart emphasizes the use of hand-picked ingredients and small-batch blending to create formulas that reflect the latest in nutrition science and breastmilk research. Their products are designed to support babies' health and provide parents with peace of mind, offering choices that help establish a strong foundation for future well-being.
Orca AI is a United States-based company that specializes in developing software solutions for the maritime industry. The company's primary focus is on enhancing vessel safety by providing an intelligent navigation system that detects, analyzes, and alerts users to dangerous scenarios in waterways and deep waters. By leveraging artificial intelligence and data from various sources, Orca AI's system creates comprehensive situational awareness, helping to predict hazards and prevent collisions. This approach aims to reduce human errors in navigation, ultimately enabling crews to make more informed decisions and promoting safety in maritime operations.
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs.
The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models.
Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders associated with neuronal imbalance. The company's lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently undergoing Phase IIa clinical trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy, and a program for KCNT1 GOF epilepsy. The company engages in collaborations and licensing agreements with various partners, including RogCon Inc., Purdue Neuroscience Company, and Ionis Pharmaceuticals. Founded in 2015, Praxis Precision Medicines is headquartered in Cambridge, Massachusetts.
SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation, providing organizations with tools to enhance their security posture. Founded in 2014 and based in Sunnyvale, California, with an additional location in Tel Aviv, Israel, SafeBreach offers a comprehensive platform that simulates hacker techniques to identify vulnerabilities within a network. Its platform utilizes an extensive Hacker's Playbook, which includes real-world breach methods, to proactively predict potential attacks and validate existing security controls. By integrating with various security information and event management systems and other cybersecurity tools, SafeBreach enables continuous visibility into security issues, allowing businesses to detect and remediate potential breaches before they can be exploited by actual attackers. The company is supported by notable investors, including Sequoia Capital and Deutsche Telekom Capital.
ByHeart, Inc. is an infant nutrition company that develops a range of nutritional food products for infants and babies, focusing on immune, microbiome, cognitive, and digestive health. Founded in 2016 and headquartered in New York, the company operates facilities in Pennsylvania. ByHeart emphasizes the use of hand-picked ingredients and small-batch blending to create formulas that reflect the latest in nutrition science and breastmilk research. Their products are designed to support babies' health and provide parents with peace of mind, offering choices that help establish a strong foundation for future well-being.
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs.
The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models.
Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.
Figure8 Inc. is a New York-based company that operates a recreational facility featuring attractions themed around frozen desserts, alongside games and crafts. Founded in 2016 by Manish Vora and Maryellis Bunn, the company focuses on creating immersive experiences that foster connections among people and enhance their interactions with various environments. Figure8 aims to reignite relationships through imaginative and creative offerings, positioning itself as an experience-first development company dedicated to enriching social engagement.
Ossio Inc., founded in 2014 and headquartered in Woburn, Massachusetts, develops and manufactures innovative orthopedic medical devices. The company specializes in OSSIOfiber, a bio-integrative implant designed for bone regeneration. Ossio aims to revolutionize the orthopedic fixation market, which includes screws, pins, and plates, by providing a non-permanent alternative to traditional metal implants. Their Intelligent Bone Regeneration Technology seeks to enhance patient healing and restore stability and mobility without leaving permanent materials behind. OSSIOfiber is engineered to offer the mechanical strength needed for secure fixation while promoting natural bone growth, thereby addressing the shortcomings of existing bio-resorbable materials that often lead to inflammation and weakness. Through its advancements, Ossio is positioned to transform orthopedic care for patients, healthcare providers, and payors alike.
Invoice2go is a technology company focused on simplifying the business processes of small business owners and freelancers worldwide. The platform provides essential tools for creating estimates and invoices, managing appointments, and tracking jobs, all designed to enhance organization and professionalism. Users can also accept various payment methods directly through the application, facilitating cash flow management and business growth. Founded by a small business owner with ties to trades, Invoice2go aims to empower its users by streamlining their operations. The platform is utilized by over 210,000 small business owners across more than 160 countries, enabling them to send approximately $24 billion in invoices annually. With a team based in Redwood City, California, and Sydney, Australia, Invoice2go combines expertise from various industries to continuously improve its offerings.
Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.